Literature DB >> 25429348

Synthesis and cytotoxicity evaluation of novel pyrido[3,4-d]pyrimidine derivatives as potential anticancer agents.

Linyi Wei1, Sanjay V Malhotra1.   

Abstract

A new series of 4-substituted 2-amino pyrido[3,4-d]pyrimidine derivatives has been designed and synthesized as potential anticancer agents. These compounds were prepared from a common intermediate, 4-chloro-8-methoxy pyrido[3,4-d]pyrimidin-2-amine, followed by palladium catalyzed cross-coupling reactions or nucleophilic aromatic substitutions at the C-4 position. Evaluation of the representative analogs using the US National Cancer Institute's 60 human cancer cell line (NCI 60) panel identified some of these compounds as exhibiting highly selective activities against breast cancer and renal cancer cell lines. A structure-activity relationship (SAR) study was explored to facilitate further development of this new class of compounds.

Entities:  

Year:  2012        PMID: 25429348      PMCID: PMC4241966          DOI: 10.1039/C2MD20097J

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  15 in total

Review 1.  Ba/F3 cells and their use in kinase drug discovery.

Authors:  Markus Warmuth; Sungjoon Kim; Xiang-ju Gu; Gang Xia; Francisco Adrián
Journal:  Curr Opin Oncol       Date:  2007-01       Impact factor: 3.645

2.  Cancer biomarkers--an invitation to the table.

Authors:  William S Dalton; Stephen H Friend
Journal:  Science       Date:  2006-05-26       Impact factor: 47.728

3.  A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants.

Authors:  David R Huron; Mercedes E Gorre; Alan J Kraker; Charles L Sawyers; Neal Rosen; Mark M Moasser
Journal:  Clin Cancer Res       Date:  2003-04       Impact factor: 12.531

Review 4.  The NCI60 human tumour cell line anticancer drug screen.

Authors:  Robert H Shoemaker
Journal:  Nat Rev Cancer       Date:  2006-10       Impact factor: 60.716

5.  Cancer statistics, 2012.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2012-01-04       Impact factor: 508.702

6.  Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial.

Authors:  M Shibuya; Y Suzuki; K Sugita; I Saito; T Sasaki; K Takakura; I Nagata; H Kikuchi; T Takemae; H Hidaka
Journal:  J Neurosurg       Date:  1992-04       Impact factor: 5.115

Review 7.  Factors underlying sensitivity of cancers to small-molecule kinase inhibitors.

Authors:  Pasi A Jänne; Nathanael Gray; Jeff Settleman
Journal:  Nat Rev Drug Discov       Date:  2009-07-24       Impact factor: 84.694

8.  Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP).

Authors:  R J Griffin; S Srinivasan; K Bowman; A H Calvert; N J Curtin; D R Newell; L C Pemberton; B T Golding
Journal:  J Med Chem       Date:  1998-12-17       Impact factor: 7.446

9.  Folate antagonists. 21. Synthesis and antimalarial properties of 2,4-diamino-6-(benzylamino)pyrido[3,2-d]pyrimidines.

Authors:  N L Colbry; E F Elslager; L M Werbel
Journal:  J Med Chem       Date:  1985-02       Impact factor: 7.446

10.  New thiopyrazolo[3,4-d]pyrimidine derivatives as anti-mycobacterial agents.

Authors:  Lluis Ballell; Robert A Field; Gavin A C Chung; Robert J Young
Journal:  Bioorg Med Chem Lett       Date:  2006-12-22       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.